News
Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...
After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...
Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...
Sanofi announced an expansion of its partnership with McLaren Racing. The two companies, alongside United Autosports, are ...
AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...
Clinical Trials Arena on MSN2d
Sanofi exec tells biotechs not to scrimp on clinical trial designIt is vital for biotech companies to run the right clinical trial and not cut costs with trial design or patient recruitment, ...
Sanofi ends antibody partnership with IGM Biosciences, while Lilly extends Purdue University collaboration with $250M ...
Moody’s Ratings has upgraded the long-term issuer rating and senior unsecured ratings of Sanofi (NASDAQ:SNY) from A1 to Aa3.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback